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Maximal Androgen Ablation: A Review

Brian J. Miles, MD,* and Joseph Babiarz, MD^

Primary management of advanced (stage D) adenocarcinoma ofthe prostate is androgen ablation.
Since this principle was discovered in the early 1940s, therapeutic alternatives and "progress" have
centered around different ways to obtain castrate levels of androgens. The role of adrenal androgens
in supporting prostate or prostatic cancer growth has been debatedfor decades and until recently was
believed to be minimal. In the 1980s the concept of maxinium androgen suppression, involving both
the testes and adrenal glands, was reintroduced with some investigators claiming exceptional resulls.
We review studies that have examined this concept, with emphasis on the largest trial which was
carried out by the National Cancer Institute. (Henry Ford Hosp MedJ 1992:40:114-7)

I

n 1941 Huggins and Hodges (1) published their landmark
paper on the effects of androgen withdrawal on advanced
adenocarcinoma of the prostate. This early work was the first to
establish the hormone dependency of a human cancer. Since
then, the endocrine physiology of the prostate has been well defined (Fig 1) (2). The testes, under direct control of the pituitary,
produce testosterone, the main androgen support of the prostate.
The remaining androgens in males are produced by the adrenal
glands primarily as androstenedione. A total of 95% of circulating androgens are in the form of testosterone. The therapeutic
options to ablate or suppress androgens include bilateral orchiectomy (castration) and administration of estrogens, luteinizing hormone-releasing hormone (LHRH) agonists, or various
antiandrogens.
Bilateral orchiectomy has been the mainstay of therapy for
advanced prostate carcinoma since the time of Huggins and
Hodges. The procedure is simple, effective, and immediate. The
major difficulty has been the psychological effect of significant
body image changes associated with this procedure. Estrogen
therapy had been the main altemative to castration until the past
tive years.
Estrogen therapy induces a "pharmacological castration" by
suppressing the hypothalamic-pituitary stimulation of the testis.
A number of studies have shown that the cardiovascular side effects of estrogens in males are severe, with cardiovascular death
occuning in up to 15% of patients (3,4). LHRH agonists have
become the main altemative to castration because with their use
cardiovascular toxicity is essentially zero (5). The pituitary is responsive to intermittent stimulation by LHRH from the hypothalamus, but when subjected to constant stimulation by LHRH
(or a long-acting LHRH agonist) the pituitary is desensitized
and stops secreting luteinizing hormone (LH). Accordingly,
LHRH agonists have the paradoxic effect of suppressing LH
production, inducing pharmacologic castration.
Antiandrogens have various mechanisms of action. The mo.st
popular,flutamide,competitively inhibits the uptake of dihydrotestosterone (the active form of testosterone) by the prostate
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nuclear receptor (6). Because the prostate cells cannot bind
dihydrotestosterone, DNA transcription cannot take place and
cellular reproduction is prevented. Because the agent is a competitive inhibitor, it acts to release the "balanced" levels of LH
and serum testosterone rises. Flutamide has not been approved
as monotherapy owing to concems that its competitive inhibiting effects might be overcome by increasing testosterone. Such
result has not yet been observed in small, nonrandomized clinical trials. An advantage of flutamide as monotherapy is due to
the fact that serum testosterone levels remain in the upper normal range and sexual libido is not impaired.
Alt primary methods to achieve androgen deprivation in patients with advanced prostate carcinoma are equally effective as
monotherapy, with approximately 80% objective respon.se rate
(7). In 10% of patients the disease progresses as if they had received no treatment, but 10% survive 10 or more years with no
evidence of progressing disease. Generally, even in patients
who respond, the disease progresses at a median of 18 months to
2 years, and median survival is approximately 30 months.
The reason patients fail androgen ablation has been the source
of much investigation. Huggins and Scott (8) suggested that adrenal androgens must be supporting the prostate carcinoma and
they attempted bilateral adrenalectomy in patients whose disease progressed after castration. Along with other investigators,
however, they demonstrated that either hypophysectomy or
adrenalectomy was ineffective with objective response rates of
only 6% to 7% (7).
Patients who fail primary ablation of testicular androgen must
do so either because the cancer includes an androgen-independent clone of cells or, altematively, a clone which is "supersensitive" to androgen has been setected and proliferated (9). If
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Fig 1—The mechanism of action of androgen on target tissues.
The plasma factors affecting androgen action are shown by
numbers ofl) luteinizing hormone-releasing hormone (LHRH),
2) luteinizing hormone (LH), 3} testosterone (T), 4}prolactin, 5)
ACTH, and 6) adrenal androgens—A^-androstenedione anddehydroepiandrosterone (DHEA and DHEA sulfate). Intracellular-mediated androgen action is shown hy the various symbols
depicted within the prostate cell. These include T conversion to
dihydrotestosterone (DHT) by 5a-reductase. 7) conversion of
adrenal androgens, A^-androstenedione and DHEA to DHT, 8)
binding of DHT derived from T and adrenal androgens to receptor to form the DHT-receptor complex, and 9) translocation
of DHT-receptor complexes to nucleus and binding to acceptor
site; 10) new protein synthesis is shown by M-RNA and prostate
acid phosphatase (PAP), prostatic specific protein (PSP). 5areductase, and so forth. (Erom Geiler J. Megestrol acetate plus
low-dose estrogen in the management of advanced prostate carcinoma. Urol Clin North Am 1991 ;18:83-91. Reprinted with
permission.)

minimally androgen-dependent clones do prevail, stimulation
by adrenal androgens could be supporting cellular growth.
Labrie and Veilleux (10) showed varying degrees of androgen
sensitivity in the Shionogi mouse model of prostate carcinoma
(Fig 2). Geiler and associates (11) also demonstrated that while
castration reduced the level of serum testosterone > 95%, intracellular dihydrotestosterone decreased by only approximately
60%. These data suggest that adrenal androgens have a more important role than was postulated by earlier investigators.
Based on the above studies, and because all eariier studies on
the effect of ablating adrenal androgens were performed after
primary testicular ablation had failed, Labrie recommended that
primary treatment of advanced prostate cancer include simultaneous ablation of both testicular and adrenal androgens. It was
believed that such treatment would eradicate all clones of cells,
even with varying androgen sensitivity. This theory was not
widely accepted by the urologic community because much data
existed, both animal and human, which showed no benefit from
combined androgen ablation. At least two animal studies utilizing rat Dunning prostate cancer models should be cited; 1) castration alone versus castration plus cyproterone acetate (an antiandrogen), and 2) LHRH agonist alone versus an LHRH ag-
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Fig 2—Response of four clones of cells to differing DHT levels
in Shionogi mouse mammary tumor. (From Labrie F, Veilleux
R. A wide range of sensitivities to androgens develops in cloned
Shionogi mouse mammary tumor cells. Prostate 1986;8;293300. Reprinted with permission.)

onist plusflutamide.No change in tumor weight was observed
either with the monotherapy androgen ablation or with the combination therapies (12,13). A few small clinical trials (fewer
than 20 patients in each arm) have evaluated the possible benefit
of complete androgen blockade, tn these .studies the rate of progression one year after castration was the same in patients receiving an LHRH agonist, an antiandrogen, or no adjuvant therapy at all (7).
Nonetheless, Labrie et al (14-16) also conducted clinical trials and claimed impressive results. These data and public pressure led the National Cancer Institute (NCI) to begin a large
multicenter intergroup study of combined therapy enlisting the
efforts of the National Prostate Cancer Project, Southwest Oncology Group, Northem Califomia Oncology Group, Mid Atlantic Oncology Program, and the North Central Cancer Treatment Group (17). A total of 617 patients with newly diagnosed
stage D2 adenocarcinoma of the prostate were randomized in a
double-blind fashion to receive either an LHRH agonist (leuprolide) plus placebo, or leuprolide plus the antiandrogen flutamide. There were 306 patients randomized to placebo and 311
toflutamide.Three patients in each arm were randomized to receive no treatment. Evaluable patients included 272 from the
placebo arm and 282 from the flutamide arm. Endpoints of the
study were response, time to first evidence of failure, and survival. Patients were evaluated every three months by bone scan,
serum acid phosphatase level, and performance status. Progression was defined as objective evidence of new disease in bone or
soft tissue or a measurable increase in old disease. Patients were
stratified by extent of disease and performance status; minimal
disease included those with axial, skeletal, and pelvic involvement only; extensive disease included patients with long bone,
skull, rib, or visceral/soft tissue (lung) metastases.
The results demonstrated a significant improvement in progression-free survival (16,5 versus 13,9 months) as well as in ul-
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Fig 3—National Cancer Institute Intergroup Protocol 0036;
Survival classified by stratification and randomized treatment
(December 1990). (Crawford ED, Eisenberg MA, McLeod DG,
et al. A controlled trial of leuprolide with and without flutamide
in prostatic carcinoma. N Engl J Med 1989;321 ;419-24. Reprinted with permission.)

Fig 4—National Cancer Institute Intergroup Protocol 0036:
Progression-free survival classified by stratification and randomized treatment (December 1990). (Crawford ED, Eisenberg
MA, McLeod DG, etal. A controlled trial of leuprolide with and
without flutamide in prostatic carcinoma. N Engl J Med 1989;
321 ;419-24. Reprinted with permission.)

timate survival (35.6 versus 28.3 months) for the flutamide
group (Figs 3 and 4) (P value for each evaluation < 0.01). Although they are statistically significant, the results have been
considered to be cHnically insignificant by the medical community. However, the results do indicate that, in the good performance status, minimal disease group, combination therapy was
associated with dramatically improved results compared to the
group receiving placebo. At 60 months the median progressionfree survival had not been reached in theflutamidegroup, but
was onty 19.1 months in the placebo group. Median survival
was 39.6 months for the placebo group, but, at 60 months, had
not yet been determined forflutamidetteatedpatients. Although
the number at risk is small, these results wanant further investigation.
Other randomized trials of maximal androgen ablation have
been carried out in Canada and Europe. All the studies have
problems with design and endpoint evaluation, and therefore are
not comparable to the NCI study. The Intemational Prostate
Study Group, with 568 patients randomized, is the only other
large study (18). Unfortunately, patients with locally advanced
disease but without metastatic disease were included. A total of
65% of the patients did have metastatic disease. The patients
were randomized in an unblinded fashion to receive either the
LHRH agonist zoladex alone or zoladex plusflutamide.The
preliminary results, presented only in abstract form, show no
statistically significant difference in objective response rate or
in time to progression, at a median follow-up of 30 weeks. The
report does not state how many patients were followed, how
many were excluded, or for what reasons.
The Canadian study compared patients after bilateral orchiectomy who received the antiandrogen nilutamide to patients after
orchiectomy who received placebo (19). There were 97 evaluable patients who received antiandrogen and 96 who received

the placebo. The results showed an 87% response for the nilutamide group and 61 % for the control group (P = 0.013). Median
time to progression was 11.7 months for the placebo group and
12.4 months for the nilutamide group, not a statistically significant difference. Similarly, the 5.4-month survival advantage
(24.3 versus 18.9) for the group receiving nilutamide was not
significant. The study was designed to evaluate best response,
not progression or survival. To evaluate all of these parameters,
the study would have to include at least three times as many subjects (20).
tn France, Brisset et al (21) conducted a randomized, prospective, blinded trial comparing orchiectomy and placebo versus
orchiectomy and anandron 150 mg daily or orchiectomy and anandron 300 mg daily. Patients were evaluated for best response,
progression-free survival, and ultimate survival. A total of 160
patients were studied in the three groups. Thirty-three patients
were not evaluable because they were shown to have had no metastasis on entry, had been lost to follow-up, or had medications
beginning later than three months after orchiectomy. Of the 127
patients for evaluation, 43 were in the placebo group, 46 in the
150 mg anandron group, and 38 in the 300 mg anandron group.
The objective response rate was 61% in each of the two anandron-treated groups, compared to 33% in the placebo group.
This is stated to be statistically significant, but a P value is not
given. Progression-free survival and ultimate survival were similar in all three groups. Median time to progression was 13
months in all groups, and the median time to death was 22 to 24
months in all three. The number of patients involved in this
three-arm study is small, enough to evaluate response but not
nearly enough to evaluate progression and/or survival.
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The European Organization of Research and Treatment of
Cancer (EORTC) conducted a clinical trial comparing orchiectomy versus orchiectomy plus cytoproterone acetate versus 1
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mg/day of diethylstilbestrol (DES) (22). This was an unblinded,
prospective randomized study. A total of 350 patients were entered from 16 European institutions. Eleven patients were determined to be ineligible and six were removed from the study because of treatment toxicity. Four ofthese six had received DES
and developed cardiovascular disease. Preliminary evaluation
of 241 patients showed no difference intimeto progression or in
length of survival for any of the three methods of treatment. Best
response to therapy was not reported, but the data appear to support the contention that there is no benefit from such combined
androgen ablation. As with other evaluations, the EORTC study
is not large enough to reveal the desired endpoints in a statistically significant manner.
The EORTC is cunently engaged in an unblinded randomized trial of orchiectomy versusflutamideplus the LHRH agonist zoladex (23). A total of 149 patients have been entered in
the combination arm and 148 in the orchiectomy arm. Best response, measured by bone scan, was 67% for orchiectomy and
79% for combination therapy. Mediantimeof progression was
18 months for the orchiectomy group and 26 months for the
combined therapy group (P = 0.03). In time to death, both
groups were es.sentially the same with a median of approximately 30 months. This study may be criticized for a number of
reasons. First and most important is that the investigators are not
comparing similar groups but two entirely different treatments.
Although there is suggestive indirect evidence, there is no direct
data showing equivalent effects from orchiectomy and the administration of LHRH agonists. Comparing this combination
therapy to orchiectomy is not meaningful. Furthermore, this
study, while large enough to evaluate best response, is also too
small to evaluate progression and survival statistically.
This compendium of apparently conflicting data demonstrates the difficulty of deriving meaningful conclusions. Evidence suggests a more favorable response to maximal androgen
ablation and, for patients with "minimal" disease, the chance of
improved progression-free survival as well as ultimate survival.
However, too few patients have been evaluated to provide statistical significance to the results of various treatment regimens.
Cunentiy the NCI is sponsoring another double-blinded intergroup trial comparing orchiectomy plus flutamide to orchiectomy plus placebo to see if the favorable results of the first trial
can be reproduced. This study will involve over 1,200 patients,
which should provide enough patients in each group to obtain
significant results for all parameters.
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